Why do people with HIV delay hepatitis C treatment?
Routine clinical use of DAAs highly effective and safe in people with HIV/HCV in Europe
Viral suppression protects against long-term liver damage caused by older HIV drugs
D:A:D study: long-term treatment with tenofovir associated with increased risk of serious liver disease
Abacavir/lamivudine could be driving liver damage in ART-treated patients with HIV/HCV co-infection
Sustained response to treatment reduces fatigue in hepatitis C patients
Merck combination suppresses HCV in mono-infected and co-infected patients
Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection
Six-week oral treatment can cure hard-to-treat hepatitis C patients
